Timur Ivannikov

US : Biotechnology - Biotechnology | Dropping Coverage of ANAB, GOSS, KYMR, and RCKT

US : Gossamer Bio, Inc. - GOSS | Ph 2 OLE/Ph 3 KOL Call: Enthusiasm Abounds

US : Gossamer Bio, Inc. - GOSS | Phase 3 Moving Ahead but Initial Phase 2 OLE Difficult to Interpret

US : Leap Therapeutics, Inc. - LPTX | Part B of DeFianCe in CRC Is a Go

US : Leap Therapeutics, Inc. - LPTX | Model Adjustment Following Reverse Split and Preferred Stock Conversion

US : Kymera Therapeutics, Inc. - KYMR | KT-413 / KT-333 Progress Update at ICML and KT-253 at EHA23

US : AnaptysBio, Inc. - ANAB | Thoughts on BTLA R&D Day After Catching Up With Management

US : NexImmune, Inc. - NEXI | Catching up With Management Post ASCO 2023 Update on NEXI-001 in r/r AML

US : NexImmune, Inc. - NEXI | 1Q23 Model Update: Final Data for NEXI-001 at ASCO

US : Leap Therapeutics, Inc. - LPTX | 1Q23 Model Update; DisTinGuish Part A Update at ASCO

US : AnaptysBio, Inc. - ANAB | 1Q23 Model Update: BTLA R&D Day on May 25

US : Gossamer Bio, Inc. - GOSS | 1Q23 Model Update; Thoughts on PAH OLE Data

US : Rocket Pharmaceuticals, Inc. - RCKT | 1Q23 Model Update; Longer Follow-Ups Across Studies at ASGCT

US : Kymera Therapeutics, Inc. - KYMR | Upgrading to Outperform on Improved Risk/Reward Setup

US : Kymera Therapeutics, Inc. - KYMR | Key Takeaways From BioPharma CEO Strategy Series Call

US : NexImmune, Inc. - NEXI | 4Q22 Model Update and 2023 Outlook

US : Leap Therapeutics, Inc. - LPTX | 4Q22 Model Update and 2023 Outlook

US : 89bio, Inc. - ETNB | 4Q22 Update: Here's the Hurdle for NASH Data

US : Gossamer Bio, Inc. - GOSS | Downgrade to Market Perform; Merck's Data Push Us Over the Edge

US : AnaptysBio, Inc. - ANAB | 4Q22 Model Update: New Studies on Track for 2Q23 / 3Q23 Initiation

US : Rocket Pharmaceuticals, Inc. - RCKT | 4Q22 Model Update; Pivotal Danon Study Still Expected in 2Q23

US : Kymera Therapeutics, Inc. - KYMR | 4Q22 Update: Oncology Updates On Track in 2023

US : Apellis Pharmaceuticals, Inc. - APLS | C'est Approuvé

US : VBI Vaccines Inc. - VBIV | First Look at VBI-2601 (Tx Vaccine) Combo Study in Chronic HBV

US : Biotechnology - Biotechnology | Takeaways From Angiogenesis 2023 and Our Pre-Event KOL Call